drugset / Trial / NCT05320874
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human, 2-part study to investigate the safety, tolerability, pharmacokinetics and efficacy of KM257 by itself and combined with selected chemotherapy agents in patients with advanced HER2-positive or expressing cancers.
Timeline
- Start
- 2022-04
- Primary completion
- 2024-06
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KM257 | Unknown | 3 mg/kg | Intravenous |
| Subject | KM257 | Unknown | 6 mg/kg | Intravenous |
| Subject | KM257 | Unknown | 12 mg/kg | Intravenous |
Indications
No indication recorded.